Clinical scenarios-based guide for tofacitinib in rheumatoid arthritis

por Mortezavi, Mahta, Mysler, Eduardo F.
Publicado 2023

Successful treatment of refractory eosinophilic fasciitis with reslizumab

por Mortezavi, Mahta, Barrett, Mary, Edrissian, Mohammadomid
Publicado 2020

Use of Tofacitinib in the Context of COVID‐19 Vaccination: Comment on the American College of Rheumatology Clinical Guidance for COVID‐19 Vaccination in Patients With Rheumatic and...

por Mortezavi, Mahta, Menon, Sujatha, Lee, Kristen, Rivas, Jose
Publicado 2021

After 25 years of drug development, do we know JAK?

por Mortezavi, Mahta, Martin, David A, Schulze-Koops, Hendrik
Publicado 2022

Patient satisfaction with telemedicine encounters in an allergy and immunology practice during the coronavirus disease 2019 pandemic

por Mustafa, S. Shahzad, Yang, Luanna, Mortezavi, Mahta, Vadamalai, Karthik, Ramsey, Allison
Publicado 2020

Rheumatology Patient Satisfaction With Telemedicine During the COVID-19 Pandemic in the United States

por Mortezavi, Mahta, Lokineni, Sravani, Garg, Megha, Chen, Ya Li, Ramsey, Allison
Publicado 2021

Fracture in clinical studies of tofacitinib in rheumatoid arthritis

por Hansen, Karen E., Mortezavi, Mahta, Nagy, Edward, Wang, Cunshan, Connell, Carol A., Radi, Zaher, Litman, Heather J., Adami, Giovanni, Rossini, Maurizio
Publicado 2022

Rheumatoid arthritis disease activity and adverse events in patients receiving tofacitinib or tumor necrosis factor inhibitors: a post hoc analysis of ORAL Surveillance

por Karpouzas, George A., Szekanecz, Zoltán, Baecklund, Eva, Mikuls, Ted R., Bhatt, Deepak L., Wang, Cunshan, Sawyerr, Gosford A., Chen, Yan, Menon, Sujatha, Connell, Carol A., Ytterberg, Steven R., Mortezavi, Mahta
Publicado 2023